Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that that the national price for KidneyIntelX™ set by the Centers for Medicare and Medicaid Services ("CMS") became effective as of 1 January 2020.

Download  full announcement US National pricing of $950 effective as of January 1 st , 2020 Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that that the Centers for Medicare and Medicaid Services (“CMS”) has released

Download  full announcement  Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the Remuneration Committee agreed to issue options over a total of 50,000 ordinary shares of £0.0025 each in the capital of the Company

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it is participating in a London based event focused on Kidney Health that will bring together senior officials from leading health

Download  full announ c ement Effective October 16, KidneyIntelX will be covered for reimbursement for qualified members Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that Capital District Physicians’ Health Plan,

Download  full  announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board. Dr.

Download  full announ c ement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that CPT reimbursement code 0105U for its  KidneyIntelX™  test has become effective nationally in the United States as of October 1, 2019. 

Download  full announement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it expects to appoint an additional non-executive director and healthcare industry veteran within the coming weeks.

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Centers for Medicare & Medicaid Services (“CMS”) has published its preliminary determination for national Medicare pricing for the

Download  full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces at its annual general meeting held earlier today, the following resolutions were passed on a show of hands with the table below summarising